Global Innovative Platforms Inc. · OTC:GIPL
Global Innovative Platforms — Investor Presentation (November 2025)
20 slides from Global Innovative Platforms's investor presentation, Nov 24, 2025
Slide 1: Vet Breath Analytics (VBA): A Diagnostic Revolution
Vet Breath Analytics (VBA) A Division Of Global Innovative Platforms Inc. (OTC: GIPL) A Diagnostic Revolution
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes "forward-looking statements.” To the extent that the information presented in this presentation discusses financial projections, information, or expectations about our business plans, results of operations, products or markets, or otherwise makes
Slide 3: Breathomics
Breathomics The study of volatile organic compo exhaled breath. Metabolism prod change with disease states, allowi offer a non-invasive diagnostic o
Slide 4: How It Works
HOW IT WORKS VOCs are exhaled in specific combinations and proportions, producing a distinct eR > “breath marker” Disease states produce specific combinations of volatile organic eon > compounds (VOCs) ' Gas chromatography unit detects > @eeeee Disease-specific VOC breath markers iw
Slide 5: Human Breathomics Uses & Research
HUMAN BREATHOMICS USES & RESEARCH (NON GIPL AFFILIATED) oo so Diabetes Breath Acetone Several Multiple trials for Diabetes Urea Breath Test companies have show breath VOC (Ketoacidosis (for Helicobacter developed Monitoring) - pylori) - FDA- breath-based COVID tests; profiles can detect lung cancer.
Slide 6: Using Breathomics to Diagnose Heartworm Disease
USING BREATHOMICS AHS RECOMMENDATIONS TO D | AG N Os E The American Heartworm Society recommends that all dogs 6 months and older be tested annually for H EARTWORM DIS EAS E heartworm di: Current jard is a blood test. An Ideal Animal Health Starting Point 6 MONTH DETECTION LAG INFECTION DETECTION >
Slide 7: Traditional Heartworm Diagnostics for Animals
TRADITIONAL HEARTWORM DIAGNOSTICS FOR ANIMALS Invasive Specialized skills Blood samples Ongoing consumables Risk of human needle sticks
Slide 8: Breathomics Testing
BREATHOMICS TESTING Non-invasive No specialized training No reagents or other consumables Results in minutes
Slide 9: Why Is Early Detection Important?
WHY IS EARLY DETECTION IMPORTANT? ¢ Identify heartworm before lasting damage occurs ¢ Protect the heart and lungs from irreversible harm ¢ Act early with prevention instead of costly treatment e Reduce financial burden and medical risk for owners e Provide veterinarians with the first early-stage sc
Slide 10: The VOCAM Plus Advantage
THE VOCAM PLUS ADVANTAGE One PPB Sensitivity Exclusive Licensing Military Research 1 part per billion sensitivity 1000x more sensitive than other gas chromatography tests GIPL holds the exclusive, worldwide license to implement the VOCAM for use in animal health applications A branch of the military
Slide 11: Massive Market Opportunity
MASSIVE MARKET OPPORTUNITY Current $3B+ animal diagnostics market) 6.8% ° ° ° 8 “ Animal diagnostics market growth 30K+ Target: 30K+ veterinary practices in US & 4k Animal Shelters. Practices e) 19M annual heartworm tests reported in the US’ CAPC estimates over 60M tests are performed annually in th
Slide 12: A Scalable Hardware/Software Enabled Solution
A SCALABLE HARDWARE/SOFTWARE ENABLED SOLUTION HEARTWORM MARKET (ONLY) AVERAGE VBA BREAKEVEN AT 205 TESTING CLINICS PROJECTED TO GENERATE $43,800 ANNUAL REVENUE HEARTWORM TEST TOTAL DAILY HW TESTS POR VER IEENIDERFORMINGHTERETe COST TO PRACTICE FROM ALL LOCATIONS PER DAY
Slide 13: A Scalable Hardware/Software Enabled Solution
A SCALABLE HARDWARE/SOFTWARE ENABLED SOLUTION COMPLETE PARASITE PANEL (5 TESTS) AVERAGE FULL PANEL TEST VBA BREAKEVEN AT 41 AVERAGE LOCATION GENERATES $219,000 ANNUAL REVENUE FOR VBA COST TO PRACTICE DAILY TOTAL TESTS AI ENIGEREORMINGHIEIRANEIGICERIA RY FROM ALL LOCATIONS te.).
Slide 14: 2026 Pilot to Launch: Regional Research Pilot Partner Clinics
2026 - PILOT TOLAUNCH 12 REGIONAL RESEARCH - PILOT PARTNER CLINICS e VBA PROVIDES VOCAM PLUS UNIT TO CLINIC e CLINICS SAMPLES OTHER PARASITES FOR RESEARCH DATA e ADDITIONAL SAMPLES SAVE R&D COSTS, IMPROVE ACCURACY, AND ACCELERATE DEVELOPMENT ¢ CLINIC RECEIVES $8 CREDIT FOR EACH PARASITE SAMPLE COLLE
Slide 15: Launch Schedule
LAUNCH SCHEDULE e COMPLETEMATURE © COMPLETE ACCURACY ¢ COMPLETE FULL © CONTINUE HW MARKER TESTING FOR HW PARASITE PANEL COMMERCIALIZATION ¢ COMPLETE EARLY e INITIATE PILOT LAUNCH e BEGIN ¢ R&D EXPANSION HW MARKER COMMERCIALIZATION
Slide 16: Vet Practice Ownership
VET PRACTICE OWNERSHIP 30,000+ VETERINARY PRACTICES IN U.S. (2025) LARGE GROUP OWNERS LARGE GROUP OWNERS 6,700+ CLINICS CAREVET (200) PETVET (450) THRIVE (455) MARS (2500) SOUTHERN VET (750) NVA (1500) VETCOR (850) *AS AQUISITIONS OCCUR, ALL NUMBERS ARE APPROXIMATIONS
Slide 17: Proven Traction
PROVEN TRACTION Y) Y) Y) Y) Y) OVER $1M RAISED EXCLUSIVE 400+ SUCCESSFULLY IDENTIFIED SUCCESSFULLY DEVELOPED CANDIDATE HEARTWORMBREATH — EARLY HEARTWORM BREATH PUBLICLY TRADED WORLDWIDE LICENSE SAMPLES MARKER IN CONTROLLED RESEARCH MARKERIN RESEARCH STUDIES; (OTC: GIPL) SECURED ANALYZED SETTING (PRE
Slide 18: Andrew Brown: Founder and CEO
Andrew Brown: Founder and CEO ‘Andrew Brown - Andrew began his last venture in 2006 as a pioneer of delivery service “red He and Delivery to become a national brand and to a successful exit in 2019. The company sold as part ‘of a $32IM transaction to a public company. Dr. Lindsay Starkey: Parasitolo
Slide 19: Citations
Citations . https://pubs.acs.org/doi/10.1021/acsnano.6b04930? . https://www.nature.com/articles/s41598-025-11365-4? . https://www.sciencedirect.com/science/article/abs/pii/S1056872721002397? . https://www.accessdata.fda.gov/cdrh_docs/pdfl0/P100025b.pdf? . https://jamanetwork.com/journals/jamanetwork
Slide 20: Contact Us
CONTACT US ANDREW BROWN - CEO © 321.230.3739 e Andrew@GIPLinc.com
Global Innovative Platforms — Investor Presentation (November 2025) on 6ix